Abstract
Activating mutations of RAS genes are a common event in the genesis of a wide variety of human tumor types (for review see Barbacid 1990). It has also become increasingly clear that many tumors without RAS gene mutations have acquired genetic lesions that contribute to tumorigenesis by causing increased or prolonged activation of Ras. In this paper we review and describe studies using human and mouse cells on the association between NF1 gene loss and the development of myeloid leukemia. The NF1 gene product, neurofibromin, has GTPase activating protein (GAP) activity for Ras and thus, could negatively regulate Ras. Therefore, NF1 gene loss in myeloid cells may contribute to leukemogenesis by activating Ras.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bader, J. L. (1986). “Neurofibromatosis and cancer.” Ann. N. Y. Acad. Sci. 486: 56–65.
Bader, J. L. and R. W. Miller (1978). “Neurofibromatosis and childhood leukemia.” J. Pediat. 92: 925–929.
Barbacid, M. (1990). “Ras oncogenes: their role in neoplasia.” Eur. J. Clin. Invest. 20: 225–235.
Basu, T. N., D. H. Gutmann, J. A. Fletcher, T. W. Glover, F. S. Collins and J. Downward (1992). “Aberrant regulation of ras proteins in malignant tumor cells from type 1 neurofibromatosis patients.” Nature 356: 713–715.
Bedigian, H. G., D. A. Johnson, N. A. Jenkins, N. G. Copeland and R. Evans (1984). “Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH-2 mice.” J. Virol. 51: 586–594.
Boguski, M. S. and F. McCormick (1993). “Proteins regulating ras and its relatives.” Nature 366: 643–653.
Bourne, H. R., D. A. Sanders and F. McCormick (1990). “The GTPase superfamily: a conserved switch for diverse cell functions.” Nature 348: 125–132.
Brannan, C. I., A. S. Perkins, K. S. Vogel, N. Ratner, M. L. Nordlund, S. W. Reid, A. M. Buchberg, N. A. Jenkins, L. F. Parada and N. G. Copeland (1994). “Targeted disruption of the neurofibromatosis type -1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.” Genes Devel. 8: 1019–1029.
Buchberg, A. M., H. G. Bedigian, N. A. Jenkins and N. G. Copeland (1990). “Evi-2, a common integration site involved in murine myeloid leukemogenesis.” Mol. Cell. Biol. 10: 4658–4666.
Cawthon, R. M., L. B. Andersen, A. M. Buchberg, G. Xu, P. O’Connel, D. Viskochil, R. B. Weiss, M. R. Wallace, D. A. Marchuk, M. Culver, et al. (1991). “cDNA sequence and genomic structure of EVI-2B, a gene lying within an intron of the neurofibromatosis type 1 gene.” Genomics 9: 446–460.
DeClue, J. E., A. G. Papageorge, J. A. Fletcher, S. R. Diehl, N. Ratner, W. C. Vass and D. R. Lowy (1992). “Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (Type 1) neurofibromatosis.” Cell 69: 265–273.
Emanuel, P. D., L. J. Bates, R. B. Castleberry, R. J. Gualtieri and K. S. Zuckerman (1991). “Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.” Blood 77: 925–929.
Golub, T. R., G. F. Barker, M. Lovett and D. G. Gilliland (1994). “Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation.” Cell 77: 307–316.
Gutmann, D. H. and F. S. Collins (1993). “The neurofibromatosis type 1 gene and its protein product, neurofibromin.” Neuron 10: 335–343.
Hope, D. G. and J. J. Mulvihill (1981). “Malignancy in neurofibromatosis.” Adv. Neurol. 29: 33–56.
Jacks, T., T. S. Shih, E. M. Schmitt, R. T. Bronson, A. Bernards and R. A. Weinberg (1994). “Tumor predisposition in mice heterozygous for a targeted mutation in Nf 1.” Nature Genet. 7: 353–361.
Jacobs, A. (1992). “Gene mutations in myelodysplasia.” Leuk. Res. 16: 47–50.
Janssen, J. W. G., A. C. M. Steenvoorden, J. Lyons, B. Anger, J. U. Bohlke, J. L. Bos, H. Seliger and C. R. Bartram (1987). “RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.” PNAS 84: 9228–9232.
Jenkins, N. A., N. G. Copeland, B. A. Taylor, H. G. Bedigian and B. K. Lee (1982). “Ecotropic murine leukemia virus DNA content of normal and lymphomatous tissues of BXH-2 recombinant inbred mice.” J. Virol. 42: 379–388.
Kalra, R., D. C. Paderanga, K. Olson and K. M. Shannon (1994). “Genetic analysis is consistent with the hypothesis that NF1 limits myeloid growth through p21ras.” Blood 84: 3435–3439.
Largaespada, D. A., J. D. Shaughnessy, N. A. Jenkins and N. G. Copeland (1995). “Retroviral insertion at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf 1 expression without changes in steady state ras-GTP levels.” J. Virol. 69: 5095–5102.
Lubbert, M., J. M. Jr., G. Kitchingman, F. McCormick, R. Mertelsmann, F. Herrmann and H. P. Koeffler (1992). “Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia.” Oncogene 7: 263–268.
Neubauer, A., K. Shannon and E. Liu (1991). “Mutation of the ras proto-oncogenes in childhood monosomy 7.” Blood 77: 594–598.
Padua, R. A., G. Carter, D. Hughes, J. Gow, C. Fair, D. Oscier, F. McCormick and A. Jacobs (1988). “RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.” Leukemia 2: 503–510.
Pendergast, A. M., L. A. Quilliam, L. D. Cripe, C. H. Bassing, Z. Dai, N. Li, A. Batzer, K. M. Rabun, C. J. Der, J. Schlessinger, et al. (1993). “BCR-ABL-induced oncogenesis is mediated by direct interaction of the SH2 domain of the GRB-2 adaptor protein.” Cdl 75: 175–185.
Puil, L., J. Lui, G. Gish, G. Mbamalu, D. Bowtell, P. G. Pelicci, R. Arlinghaus and T. Pawson (1994). “Bcr-abl oncoproteins bind directly to activators of the ras signalling pathway.” EMBO J. 13: 764–773.
Sawyers, C. and C. T. Denny (1994). “Chronic myelomonocytic leukemia: Tel-a-kinase what ets all about.” Cell 77: 171–173.
Shannon, K. M., P. O’Connell, G. A. Martin, D. Paderanga, K. Olson, P. Dinndorf and F. McCormick (1994). “Loss of thenormal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders.” New Eng. J. Med. 330: 597–601.
von Lohuizen, M. and A. Berns (1990). “Tumorigenesis by slow transforming retroviruses- -an update.” Biochim. Biophvs. Acta. 1032 (2–3): 213–235.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Largaespada, D.A., Brannan, C.I., Shaughnessy, J.D., Jenkins, N.A., Copeland, N.G. (1996). The Neurofibromatosis Type 1 (NF1) Tumor Suppressor Gene and Myeloid Leukemia. In: Wolff, L., Perkins, A.S. (eds) Molecular Aspects of Myeloid Stem Cell Development. Current Topics in Microbiology and Immunology, vol 211. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85232-9_23
Download citation
DOI: https://doi.org/10.1007/978-3-642-85232-9_23
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-85234-3
Online ISBN: 978-3-642-85232-9
eBook Packages: Springer Book Archive